Healthcare
GH Research PLC(GHRS)
Live Price
Offline$22.24
+2.49% today
1Y Change
+98.57%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $1.23B
- Revenue Growth
- 0.0%
- EPS Growth
- -5.3%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
GH Research PLC (GHRS) is a Healthcare stock with a market cap of $1.23B and listed on NASDAQ. The stock last traded around $22.24 and up 98.6% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -5.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -5.3%, free cash flow -3.2% with operating margin 0.0% and ROIC -21.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines GHRS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -5.3%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.4% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +2.0% | +5.7% | +2.0% |
2026 Mar 5, 2026 | +20.7% | +5.0% | +2.3% | -4.0% |
2025 Nov 6, 2025 | +0.0% | +0.7% | +2.3% | +11.0% |
Benchmark Edge
GHRS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GHRS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GHRS Max Drawdown
-39.49%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GHRS and SPY.
Company Overview
GH Research PLC
NASDAQ Global Market
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
- Leadership
- Velichka Valcheva
- IPO Date
- Jun 25, 2021
- Employees
- 50
- Street Address
- 28 Baggot Street Lower
- Mailing
- Dublin, D02 NX43
- Region
- Dublin, IE
- Reporting Currency
- USD
- Investor Line
- 353 1 437 8443
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 4.4
Growth
- Revenue
- 0.0%
- EPS
- -5.3%
- Free Cash Flow
- -3.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -16.3%
- ROIC
- -21.7%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 34.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.